Diagnostic approach to hemolytic anemias in the adult  by Ruiz, Eloy F. & Cervantes, Miguel A.
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dult
ear Sir,
ven though hemolytic anemias (HAs) are not very common,
heir diagnosis remains a big challenge for hematologists
nd clinicians. We  hope that this summary will contribute
ith valuable information about a subject that has been lit-
le described in the medical literature, and will help to clarify
he diagnostic approach to guide speciﬁc treatment depending
n the causative condition.
It is known that HAs are a group of disorders character-
zed by a premature red blood cell (RBC) destruction (less than
20 days),1,2 that exceeds the compensatory capacity of the
one marrow to increase RBC production and keep up with
he loss.1–3 Usually HAs are diagnosed through laboratory
ests, however, the patient’s history and physical examina-
ion are crucial as they provide important information about
he presence of hemolysis and its probable etiology.3,4 For
xample, if in addition to the classic symptoms of anemia
paleness, fatigue, dyspnea, palpitations), ﬁndings such as
amilial or personal history of jaundice, exposure to toxics, leg
lcers, lymphadenopathies, hepatomegaly or splenomegaly
ay help to elucidate the cause of the anemia.1,3,4
Regarding the etiology, HAs can be classiﬁed as inherited
r acquired and when considering the site of hemolysis, RBCs
an be destroyed in the circulation (intravascular) or within
acrophages in the spleen or liver (extravascular). From the
linical perspective, HAs can be acute or chronic and according
o the location of the abnormality responsible for the hemoly-
is, they may be due to intrinsic (intracorpuscular) or extrinsic
extracorpuscular) defects.2–4 It is important to mention that
ost intrinsic defects are inherited, and most extrinsic ones
re acquired,2 however, there are some exceptions to this rule.
or example, paroxysmal nocturnal hemoglobinuria (PNH) is
n acquired HA produced by an intrinsic defect4 and glucose-
-phosphate dehydrogenase (G6PD) deﬁciency is an inherited
ntrinsic defect that is triggered by an external factor.2
Although there are different ways of approaching the diag-
osis of HAs, it is ﬁrst necessary to identify the patient with HA
nd collect data on hemolysis. The destruction of RBCs in HAs
s characterized by an increased breakdown of hemoglobinwhich results in unconjugated hyperbilirubinemia clinically
evidenced by jaundice, increased lactate dehydrogenase (cel-
lular destruction), and reticulocytosis, which is a normal
compensatory response of the bone marrow to the RBC
loss. Additionally, decreased levels of plasma haptoglobin, a
marker of RBC destruction, are evidenced1–3 regardless the
site of hemolysis (intravascular or extravascular).5 In cases
of severe acute intravascular HAs, the haptoglobin-binding
capacity reaches its saturation point, and free hemoglobin is
ﬁltered by the glomerulus and hemoglobinuria is seen.3,6 Also,
hemosiderinuria may be present in long-term intravascular
hemolysis.3,6 On the other hand, if the hemolysis is extravas-
cular, urobilinogen may appear in the urine or feces.6
Once we  have a presumptive diagnosis, a multi-step pro-
cedure is required,4 beginning with a direct antiglobulin test
(DAT) or direct Coombs test.6,7 This is the exam of choice
because it will classify the hemolysis into an immune or non-
immune etiology.6,7 Although DAT helps to categorize HAs
into two groups, results must be interpreted in the context
of the clinical conditions as some conditions may be incor-
rectly classiﬁed.7,8 This is why the DAT should be followed
by a peripheral blood smear (PBS) and an investigation of the
family history.6 A simple approach to identify and classify HAs
based on the works of González Mesones et al.6 and others3,4,8
is presented in Figure 1.
In cases of immune HAs (DAT positive), the diagnostic pos-
sibilities are limited to the presence of autoantibodies (warm,
cold or mixed), alloimmunization (as in transfusion incompat-
ibility), or drug-related (hemolysis by haptens, autoantibodies
or immune complexes). Reviewing the PBS is a critical step in
the evaluation of non-immune HAs (DAT negative). Certain
morphological abnormalities of RBCs correlate with differ-
ent pathologies. For example, schistocytes are related to
thrombotic microangiopathies or cardiac prosthetic valves,
spherocytes with hereditary spherocytosis, sickled cells with
sickle cell disease, elliptocytes with hereditary elliptocyto-
sis, echinocytes with pyruvate kinase deﬁciency, Heinz bodies
with G6PD deﬁciency, and basophilic stipplings with lead poi-
soning, thalassemia, and Wilson’s disease, among others.4
Thus, if the PBS is abnormal, the family history may identify
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Table 1 – The most common causes of hemolysis classiﬁed by type.
Defect
Intrinsic
Inherited
Enzymopathies
Hemoglobinopathies
Membranopathies
Immune-mediated
Acquired
Traumatic
Infectious
Toxic
Entrapment
Endogenous
Exogenous
Small Vessels
Big Vessels
Drug-induced
Alloimmunization
Autoimmune
hemolytic anemia
hemolytic anemia
Extrinsic
Etiology Abnormality Examples
G6PD deficiency, pyruvate kinase deciciency
Thalassemia, sickle cell anemia
Hereditary spherocytosis, elliptocytosis
Nocturnal paroxysmal hemoglobinuria
Warm antibodies [IgG]
Idiopathic, lymphoproliferative (CLL,
NHL), SLE, non-lymphoid
malignancies
Cold antibodies [IgG]
mononucleosis, lymphoproliferative
(Waldenstroms), paroxysmal cold
hemogloburina
Mixed [warm and cold antibodies]
Idiopathic, SLE, lymphoma
ABO incompatibility
By haptens
By autoantibodies
By immune complexes
Quinidine, hydrochlorothiazide,
sulfonamides, tetracycline
Prostheses
diclofenac
Valves, TIPS
Microangiophatic hemolytic anemia
TTP, HUS, HELLP, DIC
Bartonella, Babesia, Plasmodium
Clostridium
Arsenic, lead or copper poisoning
Snake or spider bite
Wilson disease
Hypersplenism
Alpha-methyldopa, L-dopa, ibuprofen,
Penicillin, cephalosporin
Idiopathic, M. pneumoniae,
•
•
•
•
•
•
•
•
Site of
hemolysis
EV
EV
IV
IV
IV
EV
IV
EV
IV
IV
IV
IV
IV
EV
EV
EV
(also EV)
or EV
G6PD: glucose-6-phosphate dehydrogenase; CLL: chronic lymphocytic leukemia; NHL: non-Hodgkin lymphoma; SLE: systemic lupus erythematous; TIPS:
transjugular intrahepatic portosystemic shunt; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; HELLP: hemolysis, elevated
liver enzyme levels, and low platelet levels; DIC: disseminated intravascular coagulation; EV: extravascular: IV: intravascular.
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Patient with 
anemia and 
characteristic
laboratory 
features of 
hemolysis 
DAT
[+] Immune-mediated HA
Autoimmune HA
Warm 
antibodies
Cold
antibodies
Mixed
Alloimmunization ABO incompatibility
Drug-induced HA
By haptens 
By autoantibodies
By immune 
complexes
[–] Nonimmune-mediated HA
 Peripheral blood 
smear 
[+] Family history 
[+] Congenital HA
Enzymopathies
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[–]
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Infectious 
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Figure 1 – A simple approach to identify and classify hemolytic anemias. DAT: direct antiglobulin test; HA: hemolytic
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8nemia; PNH: paroxysmal nocturnal hemoglobinuria.
 congenital HA including disorders of enzymes (G6PD deﬁ-
iency, pyruvate kinase deﬁciency) hemoglobin (thalassemia,
ickle cell anemia) or of the membrane (hereditary sphero-
ytosis, elliptocytosis). Likewise, traumatic hemolysis (of big
r small vessels), infectious (Bartonella,  Babesia, Plasmodium) or
oxic (exogenous or endogenous) pathologies should be taken
nto account if there is an abnormal PBS in the absence of fam-
ly history. In contrast, if the PBS is normal, hypersplenism or
NH should be considered. A detailed list of the most common
auses of hemolysis classiﬁed by type is presented in Table 1.
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